Walgreens Boots Alliance, Inc. (0LSZ.L)
USD 10.0
(2.35%)
USD 10.0
(2.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -11.27 Billion USD | -424.17% |
| 2023 | 3.47 Billion USD | -29.79% |
| 2022 | 4.95 Billion USD | -16.83% |
| 2021 | 5.95 Billion USD | 22.39% |
| 2020 | 2.84 Billion USD | -27.92% |
| 2019 | 6.75 Billion USD | -11.94% |
| 2018 | 7.67 Billion USD | 10.31% |
| 2017 | 6.95 Billion USD | -12.31% |
| 2016 | 7.92 Billion USD | 17.4% |
| 2015 | 6.75 Billion USD | 32.87% |
| 2014 | 5.08 Billion USD | 5.19% |
| 2013 | 5.33 Billion USD | 4.36% |
| 2012 | 4.63 Billion USD | -15.06% |
| 2011 | 5.45 Billion USD | 21.46% |
| 2010 | 4.48 Billion USD | 6.3% |
| 2009 | 4.22 Billion USD | -1.37% |
| 2008 | 4.28 Billion USD | 11.87% |
| 2007 | 3.82 Billion USD | 16.89% |
| 2006 | 3.27 Billion USD | 12.65% |
| 2005 | 2.9 Billion USD | 14.89% |
| 2004 | 2.54 Billion USD | 16.85% |
| 2003 | 2.2 Billion USD | 12.44% |
| 2002 | 1.93 Billion USD | 17.01% |
| 2001 | 1.66 Billion USD | 15.82% |
| 2000 | 1.45 Billion USD | 15.93% |
| 1999 | 1.22 Billion USD | 24.16% |
| 1998 | 1.02 Billion USD | 13.97% |
| 1997 | 872.6 Million USD | 16.04% |
| 1996 | 751.4 Million USD | 15.4% |
| 1995 | 651.6 Million USD | 13.78% |
| 1994 | 573.8 Million USD | 11.28% |
| 1993 | 510.9 Million USD | 15.99% |
| 1992 | 450.6 Million USD | 11.07% |
| 1991 | 405.5 Million USD | 14.35% |
| 1990 | 354.6 Million USD | 11.76% |
| 1989 | 317.3 Million USD | 11.88% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 510 Million USD | -3562.75% |
| 2024 Q1 | 585 Million USD | -76.83% |
| 2024 Q3 | 715 Million USD | 105.78% |
| 2024 Q4 | 460 Million USD | -134.13% |
| 2023 Q2 | 782 Million USD | 17.24% |
| 2023 Q4 | 1.54 Billion USD | 218.39% |
| 2023 Q1 | 667 Million USD | -55.26% |
| 2023 FY | - USD | -140.5% |
| 2023 Q3 | 484 Million USD | -38.11% |
| 2022 Q4 | 1.49 Billion USD | 134.07% |
| 2022 Q1 | 1.57 Billion USD | -8.83% |
| 2022 FY | - USD | 16.89% |
| 2022 Q3 | 637 Million USD | -58.66% |
| 2022 Q2 | 1.54 Billion USD | -2.41% |
| 2021 FY | - USD | 64.82% |
| 2021 Q1 | 1.28 Billion USD | 29.6% |
| 2021 Q2 | 1.2 Billion USD | -5.77% |
| 2021 Q3 | 1.59 Billion USD | 31.76% |
| 2021 Q4 | 1.73 Billion USD | 8.73% |
| 2020 Q4 | 990 Million USD | 68.37% |
| 2020 FY | - USD | -54.48% |
| 2020 Q1 | 1.41 Billion USD | 4.27% |
| 2020 Q2 | 1.56 Billion USD | 10.31% |
| 2020 Q3 | 588 Million USD | -62.36% |
| 2019 Q3 | 1.61 Billion USD | -21.56% |
| 2019 FY | - USD | -13.06% |
| 2019 Q2 | 2.05 Billion USD | 13.1% |
| 2019 Q1 | 1.81 Billion USD | 18.6% |
| 2019 Q4 | 1.35 Billion USD | -15.76% |
| 2018 Q2 | 2.38 Billion USD | 27.54% |
| 2018 FY | - USD | 16.13% |
| 2018 Q1 | 1.87 Billion USD | -12.58% |
| 2018 Q3 | 1.88 Billion USD | -21.05% |
| 2018 Q4 | 1.53 Billion USD | -18.64% |
| 2017 Q4 | 2.13 Billion USD | 14.69% |
| 2017 Q2 | 2.19 Billion USD | 21.79% |
| 2017 Q1 | 1.79 Billion USD | 0.0% |
| 2017 Q3 | 1.86 Billion USD | -14.88% |
| 2017 FY | - USD | -3.46% |
| 2016 Q1 | 1.94 Billion USD | -0.46% |
| 2016 Q2 | 2.35 Billion USD | 21.16% |
| 2016 Q4 | 1.79 Billion USD | -7.89% |
| 2016 FY | - USD | -2.61% |
| 2016 Q3 | 1.95 Billion USD | -17.0% |
| 2015 FY | - USD | 52.28% |
| 2015 Q4 | 1.95 Billion USD | 0.05% |
| 2015 Q3 | 1.95 Billion USD | -1.32% |
| 2015 Q2 | 1.97 Billion USD | 64.67% |
| 2015 Q1 | 1.2 Billion USD | -8.4% |
| 2014 FY | - USD | -5.52% |
| 2014 Q1 | 1.07 Billion USD | -10.39% |
| 2014 Q2 | 1.43 Billion USD | 33.49% |
| 2014 Q4 | 1.31 Billion USD | -0.91% |
| 2014 Q3 | 1.32 Billion USD | -8.13% |
| 2013 FY | - USD | 14.97% |
| 2013 Q3 | 1.19 Billion USD | -16.1% |
| 2013 Q1 | 1.02 Billion USD | 13.84% |
| 2013 Q2 | 1.42 Billion USD | 40.1% |
| 2013 Q4 | 1.2 Billion USD | 0.33% |
| 2012 Q4 | 896 Million USD | -23.35% |
| 2012 Q1 | 1.17 Billion USD | -24.26% |
| 2012 Q3 | 1.16 Billion USD | -15.78% |
| 2012 Q2 | 1.38 Billion USD | 17.93% |
| 2012 FY | - USD | -15.06% |
| 2011 Q2 | 1.46 Billion USD | 20.51% |
| 2011 FY | - USD | 21.46% |
| 2011 Q4 | 1.55 Billion USD | 27.38% |
| 2011 Q3 | 1.22 Billion USD | -16.61% |
| 2011 Q1 | 1.21 Billion USD | 20.2% |
| 2010 Q4 | 1.01 Billion USD | -7.51% |
| 2010 FY | - USD | 6.3% |
| 2010 Q3 | 1.09 Billion USD | -18.14% |
| 2010 Q2 | 1.33 Billion USD | 26.57% |
| 2010 Q1 | 1.05 Billion USD | 12.61% |
| 2009 Q2 | 1.27 Billion USD | 40.44% |
| 2009 Q3 | 1.11 Billion USD | -12.67% |
| 2009 Q4 | 936 Million USD | -15.68% |
| 2009 FY | - USD | -1.37% |
| 2009 Q1 | 905 Million USD | -4.05% |
| 2008 Q1 | 923.5 Million USD | 17.87% |
| 2008 FY | - USD | 11.87% |
| 2008 Q3 | 1.12 Billion USD | -12.78% |
| 2008 Q4 | 943.2 Million USD | -16.13% |
| 2008 Q2 | 1.28 Billion USD | 39.62% |
| 2007 Q4 | 783.5 Million USD | -24.08% |
| 2007 Q2 | 1.17 Billion USD | 41.69% |
| 2007 FY | - USD | 16.89% |
| 2007 Q3 | 1.03 Billion USD | -12.47% |
| 2007 Q1 | 832.1 Million USD | 4.71% |
| 2006 Q3 | 707.6 Million USD | -13.8% |
| 2006 FY | - USD | 12.65% |
| 2006 Q1 | 541.8 Million USD | 3.3% |
| 2006 Q2 | 820.9 Million USD | 51.51% |
| 2006 Q4 | 794.7 Million USD | 12.31% |
| 2005 Q2 | 766.2 Million USD | 58.77% |
| 2005 Q1 | 482.6 Million USD | -6.36% |
| 2005 Q3 | 630.9 Million USD | -17.66% |
| 2005 Q4 | 524.5 Million USD | -16.86% |
| 2005 FY | - USD | 14.89% |
| 2004 FY | - USD | 16.85% |
| 2004 Q2 | 664.3 Million USD | 64.02% |
| 2004 Q3 | 541.7 Million USD | -18.46% |
| 2004 Q4 | 515.4 Million USD | -4.86% |
| 2004 Q1 | 405 Million USD | -8.18% |
| 2003 Q1 | 336 Million USD | -14.72% |
| 2003 Q4 | 441.1 Million USD | -1.69% |
| 2003 Q3 | 448.7 Million USD | -24.32% |
| 2003 Q2 | 592.9 Million USD | 76.46% |
| 2003 FY | - USD | 12.44% |
| 2002 Q3 | 414.1 Million USD | -20.88% |
| 2002 Q4 | 394 Million USD | -4.85% |
| 2002 Q2 | 523.4 Million USD | 82.69% |
| 2002 Q1 | 286.5 Million USD | -15.31% |
| 2002 FY | - USD | 17.01% |
| 2001 Q4 | 338.3 Million USD | -2.08% |
| 2001 FY | - USD | 15.82% |
| 2001 Q3 | 345.5 Million USD | -20.54% |
| 2001 Q2 | 434.8 Million USD | 68.79% |
| 2001 Q1 | 257.6 Million USD | -16.88% |
| 2000 Q4 | 309.9 Million USD | -0.93% |
| 2000 Q2 | 391.2 Million USD | 86.11% |
| 2000 Q3 | 312.8 Million USD | -20.04% |
| 2000 Q1 | 210.2 Million USD | -19.28% |
| 2000 FY | - USD | 15.93% |
| 1999 Q4 | 260.4 Million USD | 1.6% |
| 1999 Q1 | 170 Million USD | -18.66% |
| 1999 FY | - USD | 24.16% |
| 1999 Q2 | 330 Million USD | 94.12% |
| 1999 Q3 | 256.3 Million USD | -22.33% |
| 1998 Q4 | 209 Million USD | 2.45% |
| 1998 Q2 | 279 Million USD | 95.1% |
| 1998 Q3 | 204 Million USD | -26.88% |
| 1998 Q1 | 143 Million USD | -15.53% |
| 1998 FY | - USD | 13.97% |
| 1997 Q2 | 237.7 Million USD | 95.64% |
| 1997 Q4 | 169.3 Million USD | -2.53% |
| 1997 FY | - USD | 16.04% |
| 1997 Q1 | 121.5 Million USD | -15.86% |
| 1997 Q3 | 173.7 Million USD | -26.92% |
| 1996 Q3 | 146.7 Million USD | -28.51% |
| 1996 FY | - USD | 15.4% |
| 1996 Q1 | 102.8 Million USD | -15.46% |
| 1996 Q2 | 205.2 Million USD | 99.61% |
| 1996 Q4 | 144.4 Million USD | -1.57% |
| 1995 Q1 | 87.1 Million USD | -21.39% |
| 1995 Q4 | 121.6 Million USD | -3.65% |
| 1995 Q3 | 126.2 Million USD | -30.04% |
| 1995 Q2 | 180.4 Million USD | 107.12% |
| 1995 FY | - USD | 13.78% |
| 1994 FY | - USD | 11.28% |
| 1994 Q1 | 70.6 Million USD | -24.57% |
| 1994 Q4 | 110.8 Million USD | -1.69% |
| 1994 Q3 | 112.7 Million USD | -27.99% |
| 1994 Q2 | 156.5 Million USD | 121.67% |
| 1993 Q3 | 101.3 Million USD | -31.18% |
| 1993 Q4 | 93.6 Million USD | -7.6% |
| 1993 Q2 | 141.9 Million USD | 130.0% |
| 1993 Q1 | 64 Million USD | -20.5% |
| 1993 FY | - USD | 15.99% |
| 1992 Q1 | 56.9 Million USD | -25.62% |
| 1992 Q4 | 80.5 Million USD | -8.94% |
| 1992 FY | - USD | 11.07% |
| 1992 Q2 | 122.4 Million USD | 115.11% |
| 1992 Q3 | 88.4 Million USD | -27.78% |
| 1991 Q4 | 75.4 Million USD | -0.65% |
| 1991 Q1 | 49.8 Million USD | -39.27% |
| 1991 Q2 | 108.9 Million USD | 118.67% |
| 1991 FY | - USD | 16.96% |
| 1991 Q3 | 77 Million USD | -29.29% |
| 1990 Q3 | 87.8 Million USD | -25.8% |
| 1990 Q1 | 63.6 Million USD | 101.59% |
| 1990 FY | - USD | 10.03% |
| 1990 Q2 | 116.7 Million USD | 87.38% |
| 1990 Q4 | 86.3 Million USD | -2.03% |
| 1989 FY | - USD | 10.39% |
| 1989 Q4 | -3.78 Billion USD | -380.27% |
| 1989 Q3 | 1.35 Billion USD | -8.53% |
| 1989 Q1 | 1.21 Billion USD | 135.05% |
| 1989 Q2 | 1.47 Billion USD | 21.87% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -6814.056% |
| Dynavax Technologies Corporation | 9.66 Million USD | 116777.012% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 11577.479% |
| Perrigo Company plc | 646.2 Million USD | 1845.28% |
| Illumina, Inc. | -608 Million USD | -1754.934% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 204.426% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | -2411.731% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 446.376% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -10765.963% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 342.319% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -30149.712% |
| Waters Corporation | 1.02 Billion USD | 1203.252% |
| Biogen Inc. | 2.37 Billion USD | 574.464% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -12799.905% |
| Evolus, Inc. | -41.81 Million USD | -26874.408% |
| Adicet Bio, Inc. | -136.53 Million USD | -8160.153% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -9486.06% |
| bluebird bio, Inc. | -167.16 Million USD | -6646.789% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -7413.257% |
| FibroGen, Inc. | -261.4 Million USD | -4214.378% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 772.51% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -25279.922% |
| Homology Medicines, Inc. | -47.75 Million USD | -23515.881% |
| Geron Corporation | -174.78 Million USD | -6352.61% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -4843.868% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -12148.178% |
| Myriad Genetics, Inc. | -67.8 Million USD | -16534.218% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -11085.496% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | -2127.467% |
| Zoetis Inc. | 3.68 Billion USD | 406.052% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -22200.878% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 1068.861% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 3734.735% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 344.897% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -31156.582% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -4803.265% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | -4139.897% |
| Verastem, Inc. | -83.16 Million USD | -13460.83% |
| Nektar Therapeutics | -243.1 Million USD | -4539.11% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -4912.645% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -12718.094% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | -2467.874% |
| OPKO Health, Inc. | -65.51 Million USD | -17114.116% |
| Exelixis, Inc. | 196.6 Million USD | 5836.462% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 2810.406% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 10511.359% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -20127.419% |
| uniQure N.V. | -253.1 Million USD | -4355.946% |
| Imunon, Inc. | -20.78 Million USD | -54167.399% |
| Blueprint Medicines Corporation | -474.61 Million USD | -2276.257% |
| Insmed Incorporated | -654.73 Million USD | -1622.518% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 2595.425% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | -3164.585% |
| TG Therapeutics, Inc. | 26.1 Million USD | 43310.728% |
| Incyte Corporation | 919.42 Million USD | 1326.635% |
| Emergent BioSolutions Inc. | -505.29 Million USD | -2131.941% |